Skip to main content
TOPICS
Videos
Provider
Payer
Pharma
Consumer
Investor
RESOURCES
Events
Jobs
Learning Center
Webinars
White Papers
REGIONS
ANZ
ASIA
EMEA
Global Edition
MORE
About
Advertise
Contact
Privacy Policy
ANZ
ASIA
EMEA
Global Edition
Sinaptica Therapeutics
Sinaptica Therapeutics obtains FDA Breakthrough Device Designation for Alzheimer's treatment
By
Jessica Hagen
|
03:22 pm |
October 20, 2022
The neurostimulation device, which is currently for investigational use only, aims to treat cognitive and functional decline in Alzheimer's patients.
